Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney Disease - Trial NCT06221059
Access comprehensive clinical trial information for NCT06221059 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shandong Suncadia Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 180 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo
Interventional
drug
Sponsor & Location
Shandong Suncadia Medicine Co., Ltd.
Timeline & Enrollment
Phase 2
Apr 01, 2024
Apr 01, 2025
Primary Outcome
Change From Baseline to Week 13 in UACR
Summary
The objective of this study was to evaluate the efficacy of HRS-1780 tablets or Henagliflozin
 Proline tablets in patients with chronic kidney disease by evaluating UACR change from
 baseline to Week 13
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06221059
Non-Device Trial